Annual Meeting

Thicker glycocalyx barrier helps cancer evade immune system

New findings could improve effectiveness of cancer immunotherapy
Nancy D. Lamontagne
March 26, 2023

One of the ways that cancer cells hide from the body’s immune system is by forming a thin surface barrier called the glycocalyx. In a new study, researchers examined the material properties of this barrier with unprecedented resolution, revealing information that could help improve current cell-based cancer immunotherapies.

Researchers engineered immune cells (NK-92) to anchor glycocalyx-editing (GE) enzymes on the surface. The modified immune cells were able to break through the glycocalyx armor of cancer cells.
Sangwoo Park, Cornell University
Researchers engineered immune cells (NK-92) to anchor glycocalyx-editing (GE) enzymes on the surface. The modified immune cells were able to break through the glycocalyx armor of cancer cells.

Cancer cells often form the glycocalyx with high levels of cell-surface mucins, which are thought to help protect the cancer cell from immune cell attack. However, a physical understanding of this barrier has remained limited, especially as it relates to cell-based cancer immunotherapies, which involve removing immune cells from a patient, modifying them to seek and destroy cancer, and then putting them back into the patient’s body.

“We found that changes in the thickness of the barrier that were as small as 10 nanometers could affect the antitumor activity of our immune cells or the engineered cells used for immunotherapy,” said Sangwoo Park, a graduate student in Matthew Paszek’s Lab at Cornell University in Ithaca, New York. “We used this information to engineer immune cells that can get through the glycocalyx, and we hope this approach could be used to enhance current cell-based immunotherapies.”
Park will present the findings at Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology, March 25–28 in Seattle.

“Our lab has advanced a powerful strategy called scanning angle interference microscopy (SAIM) for measuring the nanoscale dimensions of the cancer cell glycocalyx,” said Park. “This imaging technique allows us to understand the structural relationship of cancer-associated mucins to the biophysical properties of the glycocalyx.”

The researchers generated a cellular model to precisely control the cell-surface mucin expression to mimic the cancer cell glycocalyx. They then combined SAIM with genetic approaches to study how the surface density, glycosylation and crosslinking of cancer-associated mucins affect the thickness of the barrier at the nanoscale. They also analyzed how the glycocalyx thickness affected a cell’s resistance to attack by immune cells.

The study revealed that the thickness of cancer cells' glycocalyx is one of the major parameters determining immune cell evasion and that engineered immune cells worked better if the glycocalyx was thinner.

Based on this knowledge, the researchers engineered immune cells with special enzymes on their surface to allow them to attach to and interact with the glycocalyx. Experiments performed at the cellular level showed that these immune cells were able to overcome the glycocalyx armor of cancer cells.

Next, the researchers plan to determine whether these findings can be replicated in the laboratory and, eventually, in clinical trials.

Sangwoo Park will present this research during the Regulatory Glycosylation Spotlight Session from 2–3 p.m. PDT on Sunday, March 26, in Room 608 of the Seattle Convention Center (abstract). Contact the media team for more information or to obtain a free press pass to attend the meeting.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Nancy D. Lamontagne

Nancy D. Lamontagne is a science writer and editor at Creative Science Writing based in Chapel Hill, North Carolina.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Drugs of the future will be easier and faster to make, thanks to mRNA
News

Drugs of the future will be easier and faster to make, thanks to mRNA

Feb. 25, 2024

But researchers still have to work out a few remaining kinks.

Mouse model may help explain, treat infertility
Journal News

Mouse model may help explain, treat infertility

Feb. 24, 2024

Discovering how sperm begin the fertilization process could also identify new targets for nonhormonal contraceptives.

AI harnesses tumor genetics to predict treatment response
News

AI harnesses tumor genetics to predict treatment response

Feb. 18, 2024

Many paths lead to cancer resistance; artificial intelligence can decode them all simultaneously.

Progression of ALS linked to a membrane and an enzyme
News

Progression of ALS linked to a membrane and an enzyme

Feb. 17, 2024

Diminished activities of the enzyme TBK1 in mitochondrial-associated membrane reduces motor neurons’ tolerance to stressors, a causative factor in the disease.

From the journals: JLR
Journal News

From the journals: JLR

Feb. 16, 2024

Breaking down atherosclerotic plaque. Location matters in liver disease. A lipidomic profile drives liver disease. Read about recent papers on these topics.

Sibling study reveals mechanism for genetic disease
Journal News

Sibling study reveals mechanism for genetic disease

Feb. 13, 2024

Using proteomics experiments, researchers found that old proteins pile up in the mitochondria of people with a form of adult-onset muscular dystrophy.